ERK5‑regulated RERG expression promotes cancer progression in prostatic carcinoma

Xiong,Ying; Huang,Hui; Chen,Shaoping; Dai,Haitao; Zhang,Luying

doi:10.3892/or.2018.6852

ERK5‑regulated RERG expression promotes cancer progression in prostatic carcinoma

Authors:
- Ying Xiong
- Hui Huang
- Shaoping Chen
- Haitao Dai
- Luying Zhang
View Affiliations

Affiliations: Department of Urology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, P.R. China, Division of Anatomy, Hubei College of Chinese Medicine, Jingzhou, Hubei 434100, P.R. China
Published online on: November 5, 2018 https://doi.org/10.3892/or.2018.6852
Pages: 1160-1168

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Big mitogen‑activated protein kinase 1 [also named extracellular signal‑regulated kinase (ERK) 5] is activated by mitogens and oncogenic signals and is strongly implicated in tumorigenesis. Our previous investigation indicated that ERK5 can induce prostatic carcinoma cell proliferation by promoting entry into the S phase of the cell cycle. In the present study, microarray and western blot analysis revealed that ERK5 can inhibit Ras‑like oestrogen‑regulated growth inhibitor (RERG) protein expression and that the inhibition of RERG expression promotes prostatic carcinoma cell proliferation and migration. In addition, pathological analysis indicated that the RERG expression level was associated with the malignancy of prostatic carcinoma. Furthermore, an apoptotic assay and western blot analysis demonstrated that the downregulation of RERG expression inhibits apoptosis by regulating the protein expression levels of B cell lymphoma‑2 and c‑Myc. Moreover, a luciferase activity assay indicated that the nuclear factor‑κB pathway is associated with RERG‑mediated apoptosis in prostatic carcinoma. Therefore, these data suggested that ERK5‑regulated RERG expression plays a role in the progression of prostatic carcinoma, indicating that RERG may be a potential biomarker for the prognosis of patients with prostatic carcinoma.

View Figures

View References

1	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Torre LA, Sauer AM, Chen MS Jr, Kagawa-Singer M, Jemal A and Siegel RL: Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females. CA Cancer J Clin. 66:182–202. 2016. View Article : Google Scholar : PubMed/NCBI
4	Stangelberger A, Waldert M and Djavan B: Prostate cancer in elderly men. Rev Urol. 10:111–119. 2008.PubMed/NCBI
5	Debes JD and Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 351:1488–1490. 2004. View Article : Google Scholar : PubMed/NCBI
6	Schröder FH: Progress in understanding androgen-independent prostate cancer (AIPC): A review of potential endocrine-mediated mechanisms. Eur Urol. 53:1129–1137. 2008. View Article : Google Scholar : PubMed/NCBI
7	Engelberg D: Stress-activated protein kinases-tumor suppressors or tumor initiators? Semin Cancer Biol. 14:271–282. 2004. View Article : Google Scholar : PubMed/NCBI
8	Dent P, Yacoub A, Fisher PB, Hagan MP and Grant S: MAPK pathways in radiation responses. Oncogene. 22:5885–5896. 2003. View Article : Google Scholar : PubMed/NCBI
9	Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe BM, et al: Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery. 132:293–301. 2002. View Article : Google Scholar : PubMed/NCBI
10	Esparis-Ogando A, Diaz-Rodriguez E, Montero JC, Yuste L, Crespo P and Pandiella A: Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol. 22:270–285. 2002. View Article : Google Scholar : PubMed/NCBI
11	Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE and Leung HY: MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene. 22:1381–1389. 2003. View Article : Google Scholar : PubMed/NCBI
12	Hayashi M and Lee JD: Role of the BMK1/ERK5 signaling pathway: Lessons from knockout mice. J Mol Med. 82:800–808. 2004. View Article : Google Scholar : PubMed/NCBI
13	Xiong Y, Zhang L and Wang T: Phosphorylation of BMK1 induces prostatic carcinoma cell proliferation by promoting entry into the S phase of the cell cycle. Oncol Lett. 11:99–104. 2016. View Article : Google Scholar : PubMed/NCBI
14	Finlin BS, Gau CL, Murphy GA, Shao H, Kimel T, Seitz RS, Chiu YF, Botstein D, Brown PO, Der CJ, et al: RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. J Biol Chem. 276:42259–42267. 2001. View Article : Google Scholar : PubMed/NCBI
15	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
16	Key MD, Andres DA, Der CJ and Repasky GA: Characterization of RERG An estrogen-regulated tumor suppressor gene. Methods Enzymol. 407:513–527. 2006. View Article : Google Scholar : PubMed/NCBI
17	Habashy HO, Powe DG, Glaab E, Ball G, Spiteri I, Krasnogor N, Garibaldi JM, Rakha EA, Green AR, Caldas C, et al: RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: A marker of ER-positive luminal-like subtype. Breast Cancer Res Treat. 128:315–326. 2011. View Article : Google Scholar : PubMed/NCBI
18	Zhao W, Ma N, Wang S, Mo Y, Zhang Z, Huang G, Midorikawa K, Hiraku Y, Oikawa S, Murata M and Takeuchi K: RERG suppresses cell proliferation, migration and angiogenesis through ERK/NF-κB signaling pathway in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 36:882017. View Article : Google Scholar : PubMed/NCBI
19	Luo X, Huang R, Sun H, Liu Y, Bi H, Li J, Yu H, Sun J, Lin S, Cui B, et al: Methylation of a panel of genes in peripheral blood leukocytes is associated with colorectal cancer. Sci Rep. 6:299222016. View Article : Google Scholar : PubMed/NCBI
20	Oster B, Thorsen K, Lamy P, Wojdacz TK, Hansen LL, Birkenkamp-Demtröder K, Sørensen KD, Laurberg S, Orntoft TF and Andersen CL: Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer. 129:2855–2866. 2011. View Article : Google Scholar : PubMed/NCBI
21	Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli MP, Yates JR III, Gray NS and Lee JD: Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 18:258–267. 2010. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^ΔΔ^C^T method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Annabi B, Lachambre MP, Plouffe K, Sartelet H and Béliveau R: Modulation of invasive properties of CD133⁺ glioblastoma stem cells: A role for MT1-MMP in bioactive lysophospholipid signaling. Mol Carcinog. 48:910–919. 2009. View Article : Google Scholar : PubMed/NCBI
24	Wang YB, Zhao XH, Li G, Zheng JH and Qiu W: MicroRNA-184 inhibits proliferation and promotes apoptosis of human colon cancer SW480 and HCT116 cells by downregulating C-MYC and BCL-2. J Cell Biochem. 119:1702–1715. 2018. View Article : Google Scholar : PubMed/NCBI
25	Peng Z, Wang Y, Fan J, Lin X, Liu C, Xu Y, Ji W, Yan C and Su C: Costunolide and dehydrocostuslactone combination treatment inhibit breast cancer by inducing cell cycle arrest and apoptosis through c-Myc/p53 and AKT/14-3-3 pathway. Sci Rep. 7:412542017. View Article : Google Scholar : PubMed/NCBI
26	Wang Q, Liu S, Tang Y, Liu Q and Yao Y: MPT64 protein from Mycobacterium tuberculosis inhibits apoptosis of macrophages through NF-κB-miRNA21-Bcl-2 pathway. PLoS One. 9:e1009492014. View Article : Google Scholar : PubMed/NCBI
27	Yen TH, Hsieh CL, Liu TT, Huang CS, Chen YC, Chuang YC, Lin SS and Hsu FT: Amentoflavone induces apoptosis and inhibits NF-ĸB-modulated anti-apoptotic signaling in glioblastoma cells. In vivo. 32:279–285. 2018.PubMed/NCBI
28	Pan L, Li Y, Zhang HY, Zheng Y, Liu XL, Hu Z, Wang Y, Wang J, Cai YH, Liu Q, et al: DHX15 is associated with poor prognosis in acute myeloid leukemia (AML) and regulates cell apoptosis via the NF-κB signaling pathway. Oncotarget. 8:89643–89654. 2017. View Article : Google Scholar : PubMed/NCBI
29	Spiering D, Schmolke M, Ohnesorge N, Schmidt M, Goebeler M, Wegener J, Wixler V and Ludwig S: MEK5/ERK5 signaling modulates endothelial cell migration and focal contact turnover. J Biol Chem. 284:24972–24980. 2009. View Article : Google Scholar : PubMed/NCBI
30	Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ and Lee JD: Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature. 395:713–716. 1998. View Article : Google Scholar : PubMed/NCBI
31	Zhao Z, Geng J, Ge Z, Wang W, Zhang Y and Kang W: Activation of ERK5 in angiotensin II-induced hypertrophy of human aortic smooth muscle cells. Mol Cell Biochem. 322:171–178. 2009. View Article : Google Scholar : PubMed/NCBI
32	Lochhead PA, Gilley R and Cook SJ: ERK5 and its role in tumour development. Biochem Soc Trans. 40:251–256. 2012. View Article : Google Scholar : PubMed/NCBI
33	Antoon JW, Martin EC, Lai R, Salvo VA, Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV, et al: MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. PLoS One. 8:e692912013. View Article : Google Scholar : PubMed/NCBI
34	Sticht C, Freier K, Knöpfle K, Flechtenmacher C, Pungs S, Hofele C, Hahn M, Joos S and Lichter P: Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC). Neoplasia. 10:462–470. 2008. View Article : Google Scholar : PubMed/NCBI
35	McCracken SR, Ramsay A, Heer R, Mathers ME, Jenkins BL, Edwards J, Robson CN, Marquez R, Cohen P and Leung HY: Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene. 27:2978–2988. 2008. View Article : Google Scholar : PubMed/NCBI
36	Ramsay AK, McCracken SR, Soofi M, Fleming J, Yu AX, Ahmad I, Morland R, Machesky L, Nixon C, Edwards DR, et al: ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer. 104:664–672. 2011. View Article : Google Scholar : PubMed/NCBI
37	Ho JY, Hsu RJ, Liu JM, Chen SC, Liao GS, Gao HW and Yu CP: MicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis. Oncotarget. 8:22443–22459. 2017. View Article : Google Scholar : PubMed/NCBI
38	Cude K, Wang Y, Choi HJ, Hsuan SL, Zhang H, Wang CY and Xia Z: Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J Cell Biol. 177:253–264. 2007. View Article : Google Scholar : PubMed/NCBI
39	Yuan Y, Anbalagan D, Lee LH, Samy RP, Shanmugam MK, Kumar AP, Sethi G, Lobie PE and Lim LH: ANXA1 inhibits miRNA-196a in a negative feedback loop through NF-κB and c-Myc to reduce breast cancer proliferation. Oncotarget. 7:27007–27020. 2016. View Article : Google Scholar : PubMed/NCBI
40	Lin ML, Lu YC, Chung JG, Wang SG, Lin HT, Kang SE, Tang CH, Ko JL and Chen SS: Down-regulation of MMP-2 through the p38 MAPK-NF-kappaB-dependent pathway by aloe-emodin leads to inhibition of nasopharyngeal carcinoma cell invasion. Mol Carcinog. 49:783–797. 2010.PubMed/NCBI